Inactive Instrument

Marina Biotech, Inc. Stock OTC Bulletin Board

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

24-01-18	Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	CI
24-01-16	Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	CI

Valuation: Marina Biotech, Inc.

Market Cap	262K 236K 218K 197K 373K 24.54M 382K 2.61M 1.04M 13.14M 982K 961K 41.82M	P/E 2021	-0.11x	P/E 2022	-0.69x
Enterprise Value	8.81M 7.94M 7.34M 6.64M 12.55M 827M 12.86M 87.96M 35.06M 443M 33.08M 32.38M 1.41B	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	99.92%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Latest news: Marina Biotech, Inc.

24-01-18	Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	CI
24-01-16	Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	CI
24-01-16	Adhera Therapeutics, Inc. Announces Board Resignations	CI
23-11-20	Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-08-21	Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-06-21	Adhera Therapeutics, Inc. announced that it has received $0.105 million in funding	CI
23-05-22	Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-27	Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	CI
23-03-31	Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-30	Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
23-03-01	Adhera Therapeutics, Inc. announced that it has received $0.214285 million in funding	CI
23-02-15	Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding	CI
23-01-25	Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes	CI

More news

Press Releases: Marina Biotech, Inc.

23-10-17	BigTime Penny Stocks: OTCQB Venture Market Watchlist (WOEN, ATRX, EDXC, CBDS, OMTK)	AQ
22-09-19	Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist	AQ
22-09-09	ADHERA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K)	AQ
22-08-25	ADHERA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
22-08-15	ADHERA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

More press releases

Managers and Directors: Marina Biotech, Inc.

Director	Title	Age	Since
Charles Rice BRD	Director/Board Member	61	2020-07-09

More insiders

Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company has two drug candidates: MLR-1019 and MLR-1023. It is engaged in developing MLR-1023 (tolimidone) as a new drug for Type I Diabetes with a focus on C-peptide positive patients. Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions. MLR-1023, a lyn kinase activator, has demonstrated clinical safety and tolerability in over 700 patients in Phase IIa and Phase IIb Type 2 diabetes studies. MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-1.06%	-0.07%	+60.76%	+68.61%	68.32B
ARGENX SE	+1.30%	+7.41%	+14.79%	+92.69%	60.26B
LONZA GROUP AG	+0.39%	+0.30%	+20.04%	+98.33%	55.86B
BEONE MEDICINES AG	-0.95%	+11.17%	+22.21%	+110.93%	48.43B
IQVIA HOLDINGS INC.	-0.23%	+4.07%	+25.63%	+40.08%	45.34B
REVOLUTION MEDICINES, INC.	-6.40%	-9.51%	+181.99%	+816.79%	41.76B
CELLTRION, INC.	+1.97%	+3.50%	+25.78%	+50.98%	34.5B
GENMAB A/S	-0.56%	-0.48%	+85.57%	+65.40%	33.8B
INSMED INCORPORATED	+1.05%	+9.77%	-37.66%	+408.42%	26.21B
Average	-0.50%	+1.46%	+44.35%	+194.69%	46B
Weighted average by Cap.	-0.53%	+1.44%	+45.34%	+173.07%

	2021	2022
Net sales	-	-
Net income	-6.35M -5.72M -5.29M -4.78M -9.04M -596M -9.27M -63.38M -25.26M -319M -23.84M -23.33M -1.02B	-2.11M -1.91M -1.76M -1.59M -3.01M -198M -3.08M -21.1M -8.41M -106M -7.93M -7.77M -338M
Net Debt	6.59M 5.94M 5.48M 4.96M 9.38M 618M 9.61M 65.73M 26.2M 331M 24.72M 24.2M 1.05B	8.55M 7.71M 7.12M 6.44M 12.18M 802M 12.48M 85.35M 34.02M 430M 32.1M 31.42M 1.37B

Marina Biotech, Inc. Stock OTC Bulletin Board

Stocks

Biotechnology & Medical Research

Valuation: Marina Biotech, Inc.

Latest news: Marina Biotech, Inc.

Press Releases: Marina Biotech, Inc.

Managers and Directors: Marina Biotech, Inc.

Bio Therapeutic Drugs

Financials

Company Profile